Multiple Myeloma Treatment Guidelines

Initial Treatment Strategy

• The American Society of Clinical Oncology recommends induction therapy with bortezomib, lenalidomide, and dexamethasone (VRd), followed by autologous stem cell transplantation (ASCT) in eligible patients, and continuous lenalidomide maintenance until progression 1, 2

Transplant-Eligible Patients

• The International Myeloma Society recommends stem cell collection and transplantation with high-dose melphalan (200 mg/m²) and ASCT using peripheral blood progenitor cells as the preferred source 1
• The National Comprehensive Cancer Network recommends continuous lenalidomide maintenance until disease progression, which provides median progression-free survival of 41 months 1

Transplant-Ineligible Patients

• The European Society for Medical Oncology recommends VRd as the preferred triplet regimen, with dose modifications for elderly patients (dexamethasone reduced to 20 mg weekly for patients >75 years, with further reduction to 8-20 mg weekly for frail patients) 3
• The American College of Physicians recommends continuous therapy over fixed-duration therapy, as it improves both progression-free survival and overall survival 3

High-Risk Cytogenetics Management

• The International Myeloma Society recommends bortezomib-based maintenance therapy over lenalidomide alone for patients with high-risk cytogenetics, as bortezomib partially overcomes the adverse effects of t(4;14) and del(17p) 4

Treatment of Relapsed Disease

• The American Society of Clinical Oncology recommends triplet therapy with a monoclonal antibody-based regimen for first relapse, with daratumumab-lenalidomide-dexamethasone being the preferred option based on superior efficacy 5, 6
• The National Comprehensive Cancer Network recommends lenalidomide-refractory patients use proteasome inhibitor-based regimens (carfilzomib or bortezomib) plus daratumumab and dexamethasone 7

Prognosis

• The International Myeloma Society recommends bortezomib-based therapy for high-risk cytogenetics, which partially mitigates poor prognosis 4
• The European Society for Medical Oncology recommends daratumumab-lenalidomide-dexamethasone for first relapse, which provides superior PFS compared to doublet regimens across all cytogenetic risk groups 5

Critical Management Considerations

• The American College of Physicians recommends thromboprophylaxis, herpes zoster prophylaxis, and bisphosphonates for all patients on immunomodulatory drugs 1, 2
• The National Comprehensive Cancer Network recommends subcutaneous bortezomib preferentially over intravenous administration to prevent peripheral neuropathy 2
• The European Society for Medical Oncology recommends dose reduction of lenalidomide based on creatinine clearance for patients with renal impairment 3
• The American Society of Clinical Oncology recommends response monitoring with each treatment cycle using serum and urine protein electrophoresis and serum free light chains 8, 2